Drugs / Shigella flexneri 2a InvaplexAR
Shigella flexneri 2a InvaplexAR
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02445963 Comparator | Oct 2015 → May 2016 | shigellosis | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shigella flexneri 2a InvaplexAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02445963 ↗ |
| Known as | Artificial Invaplex | “Artificial Invaplex (InvaplexAR) is a subunit vaccine approach complexing Shigella LPS with invasion plasmid antigens.” PMID 37666695 ↗ Sep 2023 |
| Known as | Invaplex(AR) | “GMP manufacture of Shigella flexneri 2a Artificial Invaplex (Invaplex(AR)) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy,...” PMID 37666695 ↗ Sep 2023 |
| Modality | Vaccine | “S. flexneri 2a InvaplexAR vaccine” NCT02445963 ↗ |
| Route | Intranasal | “The vaccine will be administered intranasally” NCT02445963 ↗ |